Literature DB >> 17456777

Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

Brian M Dufty1, Lisa R Warner, Sheng T Hou, Susan X Jiang, Teresa Gomez-Isla, Kristen M Leenhouts, Julia T Oxford, Mel B Feany, Eliezer Masliah, Troy T Rohn.   

Abstract

Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are both characterized pathologically by the presence of neuronal inclusions termed Lewy bodies (LBs). A common feature found in LBs are aggregates of alpha-synuclein (alpha-Syn), and although it is now recognized that alpha-Syn is the major building block for these toxic filaments, the mechanism of how this occurs remains unknown. In the present study, we demonstrate that proteolytic processing of alpha-Syn by the protease calpain I leads to the formation of aggregated high-molecular weight species and adoption of a beta-sheet structure. To determine whether calpain-cleavage of alpha-Syn occurs in PD and DLB, we designed site-directed calpain-cleavage antibodies to alpha-Syn and tested their utility in several animal model systems. Detection of calpain-cleaved alpha-Syn was evident in mouse models of cerebral ischemia and PD and in a Drosophila model of PD. In the human PD and DLB brain, calpain-cleaved alpha-Syn antibodies immunolabeled LBs and neurites in the substantia nigra. Moreover, calpain-cleaved alpha-Syn fragments identified within LBs colocalized with activated calpain in neurons of the PD and DLB brains. These findings suggest that calpain I may participate in the disease-linked aggregation of alpha-Syn in various alpha-synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456777      PMCID: PMC1854966          DOI: 10.2353/ajpath.2007.061232

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.

Authors:  L C Serpell; J Berriman; R Jakes; M Goedert; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 2.  Cutting to the chase: calpain proteases in cell motility.

Authors:  Angela Glading; Douglas A Lauffenburger; Alan Wells
Journal:  Trends Cell Biol       Date:  2002-01       Impact factor: 20.808

Review 3.  Failure of the ubiquitin-proteasome system in Parkinson's disease.

Authors:  K S McNaught; C W Olanow; B Halliwell; O Isacson; P Jenner
Journal:  Nat Rev Neurosci       Date:  2001-08       Impact factor: 34.870

4.  Age-associated inclusions in normal and transgenic mouse brain.

Authors:  M Jucker; L C Walker; L J Martin; C A Kitt; H K Kleinman; D K Ingram; D L Price
Journal:  Science       Date:  1992-03-13       Impact factor: 47.728

Review 5.  Pathogenic effects of alpha-synuclein aggregation.

Authors:  Ditte Lundvig; Evo Lindersson; Poul Henning Jensen
Journal:  Brain Res Mol Brain Res       Date:  2005-03-24

6.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.

Authors:  S Kanda; J F Bishop; M A Eglitis; Y Yang; M M Mouradian
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?

Authors:  A Mouatt-Prigent; J O Karlsson; Y Agid; E C Hirsch
Journal:  Neuroscience       Date:  1996-08       Impact factor: 3.590

8.  Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

Authors:  George K Tofaris; Pablo Garcia Reitböck; Trevor Humby; Sarah L Lambourne; Mark O'Connell; Bernardino Ghetti; Helen Gossage; Piers C Emson; Lawrence S Wilkinson; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurosci       Date:  2006-04-12       Impact factor: 6.167

9.  Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Authors:  Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

10.  Altered proteasomal function in sporadic Parkinson's disease.

Authors:  Kevin St P McNaught; Roger Belizaire; Ole Isacson; Peter Jenner; C Warren Olanow
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

View more
  113 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

Review 3.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

4.  Head injury, α-synuclein Rep1, and Parkinson's disease.

Authors:  Samuel M Goldman; Freya Kamel; G Webster Ross; Sarah A Jewell; Grace S Bhudhikanok; David Umbach; Connie Marras; Robert A Hauser; Joseph Jankovic; Stewart A Factor; Susan Bressman; Kelly E Lyons; Cheryl Meng; Monica Korell; Diana F Roucoux; Jane A Hoppin; Dale P Sandler; J William Langston; Caroline M Tanner
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

Review 5.  Mitochondria, calcium and cell death: a deadly triad in neurodegeneration.

Authors:  Fulvio Celsi; Paola Pizzo; Marisa Brini; Sara Leo; Carmen Fotino; Paolo Pinton; Rosario Rizzuto
Journal:  Biochim Biophys Acta       Date:  2009-03-04

6.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

7.  Neonatal Propofol Anesthesia Changes Expression of Synaptic Plasticity Proteins and Increases Stereotypic and Anxyolitic Behavior in Adult Rats.

Authors:  Desanka Milanovic; Vesna Pesic; Natasa Loncarevic-Vasiljkovic; Vladimir Avramovic; Vesna Tesic; Vesna Jevtovic-Todorovic; Selma Kanazir; Sabera Ruzdijic
Journal:  Neurotox Res       Date:  2017-04-24       Impact factor: 3.911

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 9.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

10.  Potassium depolarization and raised calcium induces α-synuclein aggregates.

Authors:  Jordan Follett; Bonnie Darlow; Mathew B Wong; Jacob Goodwin; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-12-19       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.